Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...

The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

We all age. And while humanity's life expectancy has increased dramatically in the modern era, we still struggle with the ...

Omeros (OMER) announced an update on its progress toward planned resubmission of its biologics license application, or BLA, for narsoplimab, the company’s antibody targeting ... Following data ...